Department of Cardiology, The Second Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Nangang District, Harbin, 150086, China.
The Key Laboratory of Myocardial Ischemia, Harbin Medical University, Ministry of Education, 246 Xuefu Road, Nangang District, Harbin, 150086, China.
Cardiovasc Drugs Ther. 2021 Apr;35(2):231-247. doi: 10.1007/s10557-020-07120-8. Epub 2021 Jan 6.
The coronavirus disease 19 (COVID-19) pandemic poses a serious global threat to human health and the economy. Based on accumulating evidence, its continuous progression involves not only pulmonary injury but also damage to the cardiovascular system due to intertwined pathophysiological risks. As a point of convergence in the pathophysiologic process between COVID-19 and heart failure (HF), cytokine storm induces the progression of COVID-19 in patients presenting pre-existing or new onset myocardial damage and even HF. Cytokine storm, as a trigger of the progression of HF in patients with COVID-19, has become a novel focus to explore therapies for target populations. In this review, we briefly introduce the basis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and illuminate the mechanism and links among COVID-19, cytokine storm, and HF. Furthermore, we discuss drugs and therapeutic targets for patients with COVID-19 and HF.
新型冠状病毒病（COVID-19）大流行对人类健康和经济构成了严重的全球性威胁。基于不断积累的证据，其持续进展不仅涉及肺部损伤，还涉及由于病理生理风险交织而导致的心血管系统损伤。作为 COVID-19 和心力衰竭（HF）之间病理生理过程的交汇点，细胞因子风暴导致伴有或新发心肌损伤甚至 HF 的患者 COVID-19 的进展。细胞因子风暴作为 COVID-19 患者 HF 进展的触发因素，已成为探索目标人群治疗方法的新焦点。在这篇综述中，我们简要介绍了严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的基础，并阐明了 COVID-19、细胞因子风暴和 HF 之间的机制和联系。此外，我们还讨论了 COVID-19 和 HF 患者的药物和治疗靶点。
